萘二磺酸氯吡格雷(Clopidogrel napadisilate) - 药物靶点：P2Y12 receptor_在研适应症：血栓形成_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Clopidogrel、Clopidogrel napadisilate monohydrate、Pidogul

+ [1]

靶点

P2Y12 receptor

作用方式

拮抗剂

作用机制

P2Y12 receptor拮抗剂(嘌呤P2Y12受体拮抗剂)

治疗领域

心血管疾病

在研适应症

血栓形成

非在研适应症-

原研机构

Hanmi Pharmaceutical Co., Ltd.

在研机构

Hanmi Pharmaceutical Co., Ltd.

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

英国 (2010-12-23),

血栓形成

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C16H16ClNO2S

InChIKeyGKTWGGQPFAXNFI-HNNXBMFYSA-N

CAS号113665-84-2

查看全部结构式(2)

关联

166

项与萘二磺酸氯吡格雷相关的临床试验

ISRCTN16705062

/ Recruiting临床4期IIT

Antiplatelet Secondary Prevention International Randomised study after INtracerebral haemorrhaGe (ASPIRING): an investigator-initiated, multicentre, pragmatic, prospective, randomised, parallel group, open clinical trial of an investigational medicinal product

开始日期2025-03-01

申办/合作机构

The University of Edinburgh

SLCTR/2024/038

/ SuspendedN/A

Can a higher dose overcome clopidogrel resistance – a study of 150mg daily, in patients with abnormal platelet function with and without cyp2c19 gene polymorphism

开始日期2024-12-01

申办/合作机构

Medical Research Institute

NCT06613191

/ Not yet recruiting临床4期IIT

P2Y12 Inhibitor Versus Aspirin Monotherapy in Patients Undergoing Elective Screening and Surveillance Colonoscopy

Patients on dual antiplatelet therapy )aspirin plus a P2Y12 inhibitor [clopidogrel, prasugrel, or ticagrelor]) undergoing screening or surveilance colonoscopy are at increased risk for bleeding from the procedure. Patients are ussually asked to stop the P2Y12 inhibitor for the procedure. Currently, recommendation is that patients only on a P2Y12 inhibitor be changes to aspirin for the procedure. This pilot study will evaluate if there is a large difference in bleeding between patients only taking aspirin compared with patients only taking a P2Y12 inhibitor. Patinets who participate will randomly be randomly asked to stop either aspirin or the P2Y12 inhibitor 1 week before the procedure. Periprocedural bleeding and bleeding after the procedure for iup to 30 days.

开始日期2024-10-01

申办/合作机构-

100 项与萘二磺酸氯吡格雷相关的临床结果

登录后查看更多信息

100 项与萘二磺酸氯吡格雷相关的转化医学

登录后查看更多信息

100 项与萘二磺酸氯吡格雷相关的专利（医药）

登录后查看更多信息

10,096

项与萘二磺酸氯吡格雷相关的文献（医药）

2025-05-01·Journal of Pharmaceutical and Biomedical Analysis

Simultaneous quantification of eighteen therapeutic oral anticoagulants, rodenticides, and antiplatelet agents by LC-MS/MS and its application in post-mortem forensic cases

Article

作者: Delavenne, Xavier ; Bidat, Carolyne ; Escal, Jean ; Hodin, Sophie ; Duband, Sébastien ; Drague, Angélique ; Dellinger, Sandrine ; Feliu, Catherine

Anticoagulants and antiplatelet agents, which interfere with blood coagulation, can lead to fatal bleeding. Moreover, their widespread use as drugs or rodenticides poses a high risk of accidental or intentional poisoning. Therefore, quantifying these substances is essential in forensic investigations. This research aimed to develop and validate a liquid chromatography-tandem mass spectrometry method capable of quantifying eighteen anticoagulant or antiplatelet compounds (apixaban, rivaroxaban, dabigatran, warfarin, acenocoumarol, fluindione, brodifacoum, bromadiolone, difenacoum, difethialone, chlorophacinone, coumatetralyl, flocoumafen, acetylsalicylic acid, clopidogrel, dipyridamole, ticagrelor, and ticlopidine) in a single run with simple sample preparation. The method was validated according to the FDA recommendations for all compounds, with an eight-min run time in human whole blood, the gold standard in toxicological forensic investigation. The method was also validated for therapeutic compounds and most rodenticides in bile and vitreous humor. Following validation, the method was applied to seven forensic cases with a known history of anticoagulant or antiplatelet agent use to prove the validity of the method. This method provides a valuable tool for legal contexts where precise determination of anticoagulant compound presence and concentration is required.

2025-04-03·International Journal of Neuroscience

Effect of atorvastatin calcium plus clopidogrel in the treatment of patients with transient ischemic attacks and its effect on blood lipids and platelets

Article

作者: Bian, Maocheng ; Wan, Jian ; Zhong, Fei

OBJECTIVETo explore the clinical effect of atorvastatin calcium combined with clopidogrel in the treatment of patients with transient ischemic attacks (TIAs) and its effect on blood lipids and platelets.METHODSLow-density lipoprotein cholesterol (LDL-C)], platelet-related parameters [prothrombin time (PT), activated partial thromboplastin time (APTT), platelet count (PLT)], incidence of cerebral infarction, and adverse reactions.RESULTSThe clinical outcomes of the experimental group patients were significantly better than those of the control group patients (p < 0.05). The experimental group exhibited notably lower levels of TG, TC, and LDL-C compared to the control group (p < 0.05). Platelet-related indices-PT, APTT, and PLT-showed no significant differences between groups before and after treatment (p > 0.05). The incidence of cerebral infarction was notably lower in the experimental group (p < 0.005), while the occurrence of adverse reactions showed no significant difference between groups (p > 0.05).CONCLUSIONAtorvastatin calcium combined with clopidogrel demonstrates a positive impact on individuals with TIAs by significantly lowering levels of LDL, total cholesterol, and triglycerides. However, it is noteworthy that platelet-related indices did not exhibit significant differences between the experimental and control groups. While the observed improvements in blood lipids are attributed to the effects of atorvastatin, the combination with clopidogrel did not show a substantial influence on platelet-related parameters. Thus, the overall therapeutic impact, particularly on platelet-related indices, may require further investigation and clarification. Despite these nuances, our findings suggest potential benefits in reducing the risk of adverse reactions and cerebral infarction, supporting the consideration of this approach for wider clinical use.

2025-03-24·Angewandte Chemie International Edition

Universal Reagent for Mild and Stereospecific Nucleophilic Substitution of Alcohols with Amines

Article

作者: Dauphinais, Maxime ; Sagamanova, Irina K. ; Thai‐Savard, Léa ; Noël, Charlotte ; Régnier, Sophie ; Bechara, William S. ; Charette, André B. ; Jarvis, Scott B. D.

AbstractA user‐friendly reagent for mild and general activation of alcohols towards bimolecular nucleophilic substitution (SN2) leveraging diverse nucleophiles, including primary and secondary amines is reported herein. The new ion‐paired reagent discovery was based upon the putative zwitterionic betaine intermediate of the Mitsunobu reaction and enabled the one‐step conversion of enantioenriched alcohols to valuable chiral C−X bonds (where X=N, C, S, O or halide). The described activating reagent has also been applied to a one‐step methylation reaction using methanol and to an intermolecular amination/intramolecular cyclization sequence that generates heterocycles, such as tetrahydroisoquinolines. This work provides the first evidence by X‐ray crystallography of a protonated betaine as intermediate in the Mitsunobu reaction.

100 项与萘二磺酸氯吡格雷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	萘二磺酸氯吡格雷	B01AC04	DB00758

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
血栓形成	英国	Hanmi Pharmaceutical Co., Ltd.	2010-12-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ACS-DM Registry (ESC2023)	N/A	急性冠状动脉综合征 \| 糖尿病	539	Ticagrelor	壓艱糧糧鑰襯製鹹顧糧(齋夢繭蓋衊構製網醖範): HR = 2.53 (95% CI, 1.32 ~ 4.84), P-Value = 0.684 更多	不佳	2023-08-27
				Clopidogrel
ALPHEUS Naive sub-study (ESC2023)	N/A	不稳定型心绞痛	1,882	Ticagrelor	築膚醖膚廠糧餘繭醖蓋(淵糧糧築憲鹹鹽鏇選積) = 獵鹹膚餘鑰衊構顧鏇範構壓鑰製構醖築鏇積壓 (餘繭齋膚製築蓋繭觸築 ) 更多	-	2023-08-26
				Clopidogrel	築膚醖膚廠糧餘繭醖蓋(淵糧糧築憲鹹鹽鏇選積) = 選醖網壓齋齋餘衊獵廠構壓鑰製構醖築鏇積壓 (餘繭齋膚製築蓋繭觸築 ) 更多
ALPHEUS study (ESC2023)	N/A	不稳定型心绞痛	1,866	Ticagrelor	顧齋範製鬱憲窪衊獵遞(襯願獵願鏇繭築衊蓋齋) = 鹹蓋製糧簾簾壓鑰顧壓醖膚餘顧簾範積廠襯廠 (願襯淵餘觸鑰簾窪糧艱 ) 更多	-	2023-08-26
				Clopidogrel	顧齋範製鬱憲窪衊獵遞(襯願獵願鏇繭築衊蓋齋) = 艱鏇築願觸範繭鏇醖築醖膚餘顧簾範積廠襯廠 (願襯淵餘觸鑰簾窪糧艱 ) 更多
HOST-EXAM Extended (ESC2023)	N/A	出血 \| 血栓形成维持	-	Clopidogrel	蓋鹽醖糧積鹹廠選積衊(獵鏇遞鹹窪壓築廠鹹糧): HR = 2.7 (95% CI, 2.29 ~ 3.18)	-	2023-08-26
				Aspirin
CREA ARIAM Andalucia registry (ESC2022)	N/A	急性冠状动脉综合征	2,070	Ticagrelor	鏇膚遞網廠簾蓋夢壓遞(廠獵鏇蓋築艱夢鹹鹽選) = 製醖憲獵夢鬱憲蓋獵廠艱衊艱顧艱醖窪蓋鹹衊 (壓淵餘憲襯製獵壓醖鏇 )	-	2022-08-29
				Clopidogrel	鏇膚遞網廠簾蓋夢壓遞(廠獵鏇蓋築艱夢鹹鹽選) = 構遞艱構鏇積醖積繭觸艱衊艱顧艱醖窪蓋鹹衊 (壓淵餘憲襯製獵壓醖鏇 )
ESC2022	N/A	急性冠状动脉综合征	-	Clopidogrel SAPT	(簾艱蓋鹹鏇餘鏇簾鹽網): HR = 0.72 (95% CI, 0.54 ~ 0.98)	-	2022-08-28
				Aspirin monotherapy
ESC2022	N/A	急性冠状动脉综合征	-	Ticagrelor	(糧範膚蓋餘獵衊夢積憲): HR = 0.9 (95% CI, 0.84 ~ 0.97) 更多	-	2022-08-27
				Clopidogrel
CREA ARIAM Andalucia registry (ESC2022)	N/A	急性冠状动脉综合征	2,070	Ticagrelor	(憲淵夢鑰製繭積襯襯糧): adjusted hazard ratio = 1.4 (95% CI, 0.96 ~ 2.05)	-	2022-03-19
				Clopidogrel
CREA-ARIAM Andalucia registry (ESC2022)	N/A	急性冠状动脉综合征	2,070	Ticagrelor	願網壓願鹽鑰糧壓選餘(淵襯鹽夢顧廠蓋積襯淵) = 窪選觸構鬱糧夢衊齋範醖蓋夢構餘選顧膚襯糧 (鹹膚餘艱衊醖繭製鑰餘 )	-	2022-03-18
				Clopidogrel	願網壓願鹽鑰糧壓選餘(淵襯鹽夢顧廠蓋積襯淵) = 積壓襯膚醖廠蓋廠糧製醖蓋夢構餘選顧膚襯糧 (鹹膚餘艱衊醖繭製鑰餘 )
ISC2022	N/A	-	-	Clopidogrel bolus	構構壓淵鏇網糧廠遞壓(製蓋選願蓋夢製網顧鹽) = 繭醖餘構觸夢衊醖壓夢願鏇繭積糧範齋窪膚鏇 (夢膚糧製憲網網廠獵鹽 ) 更多	不佳	2022-02-01
				Sustained clopidogrel pre-treatment	構構壓淵鏇網糧廠遞壓(製蓋選願蓋夢製網顧鹽) = 顧醖淵鏇製壓鑰淵觸餘願鏇繭積糧範齋窪膚鏇 (夢膚糧製憲網網廠獵鹽 ) 更多